Lista de obras - Thibault Mesplède - Dominio Público Uruguay

A high-throughput assay for HIV-1 integrase 3'-processing activity using time-resolved fluorescence

artículo científico publicado en 2012

A resveratrol analog termed 3,3',4,4',5,5'-hexahydroxy-trans-stilbene is a potent HIV-1 inhibitor

artículo científico publicado en 2015

Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.

artículo científico publicado en 2014

Antimalarial drugs and their metabolites are potent Zika virus inhibitors

artículo científico publicado en 2019

Antiviral Activity of Bictegravir and Cabotegravir Against Integrase Inhibitor Resistant SIVmac239 and HIV-1.

artículo científico publicado en 2017

Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity.

artículo científico publicado en 2013

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

artículo científico publicado en 2019

Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase.

artículo científico publicado en 2014

Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase.

artículo científico publicado en 2014

Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase

artículo científico publicado en 2013

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc

artículo científico publicado en 2014

Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.

artículo científico publicado en 2015

Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir

artículo científico publicado en 2011

Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity.

artículo científico publicado en 2015

Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1

scientific article published on 05 February 2020

Correction for Anstett et al., "HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity"

article

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors

artículo científico publicado en 2016

Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors.

artículo científico publicado en 2013

Differences among HIV-1 subtypes in drug resistance against integrase inhibitors

artículo científico publicado en 2016

Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase

artículo científico publicado en 2014

Diverse Types of Diterpenoids with an Aromatized C Ring from the Twigs of Podocarpus imbricatus

artículo científico publicado en 2020

Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study

artículo científico publicado en 2017

Dolutegravir inhibits HIV-1 Env evolution in primary human cells

artículo científico publicado en 2015

Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout

artículo científico publicado en 2015

Dolutegravir monotherapy of simian immunodeficiency virus-infected macaques selects for several patterns of resistance mutations with variable virological outcomes

artículo científico publicado en 2019

Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs.

artículo científico publicado en 2017

Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions

artículo científico publicado en 2015

Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.

artículo científico publicado en 2015

Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout

article

Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors

artículo científico publicado en 2014

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses

artículo científico publicado en 2016

Erratum for Mesplède et al., "The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration"

article

Evolution of HIV integrase resistance mutations.

artículo científico publicado en 2013

Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART

artículo científico publicado en 2018

Exposure to entry inhibitors alters HIV infectiousness and sensitivity to broadly neutralizing monoclonal antibodies.

artículo científico publicado en 2014

Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency

artículo científico publicado en 2014

HIV Drug Resistance and the Advent of Integrase Inhibitors.

artículo científico

HIV drug resistance against strand transfer integrase inhibitors

artículo científico publicado en 2017

HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.

artículo científico publicado en 2012

HIV-1 Group O Resistance Against Integrase Inhibitors

artículo científico publicado en 2015

HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase

artículo científico publicado en 2014

HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M.

artículo científico publicado en 2014

HIV-1 resistance dynamics in patients failing dolutegravir maintenance monotherapy.

artículo científico publicado en 2018

HIV-1 resistance to dolutegravir is affected by cellular histone acetyltransferase activity

artículo científico publicado en 2017

Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor

artículo científico publicado en 2015

Identification of resveratrol analogs as potent anti-dengue agents using a cell-based assay

artículo científico publicado en 2016

Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy

artículo científico publicado en 2015

Inhibition of NF-κB-dependent HIV-1 replication by the marine natural product bengamide A.

artículo científico publicado en 2018

Insertion as a Resistance Mechanism Against Integrase Inhibitors in Several Retroviruses

artículo científico publicado en 2019

Integrase Strand Transfer Inhibitors in HIV Therapy.

artículo científico publicado en 2013

Integrase strand transfer inhibitors in the management of HIV-positive individuals

artículo científico

Investigational HIV integrase inhibitors in phase I and phase II clinical trials

artículo científico publicado en 2017

Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update

artículo científico publicado en 2018

Involvement of TBK1 and IKKepsilon in lipopolysaccharide-induced activation of the interferon response in primary human macrophages

artículo científico publicado en 2007

Is resistance to dolutegravir possible when this drug is used in first-line therapy?

artículo científico publicado en 2014

IκB kinase ε-dependent phosphorylation and degradation of X-linked inhibitor of apoptosis sensitizes cells to virus-induced apoptosis

artículo científico publicado en 2011

JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1.

artículo científico publicado en 2017

Lamivudine-resistant HIVM184V is durably suppressed with dolutegravir plus lamivudine dual therapy in humanised mice

artículo científico publicado en 2020

M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.

artículo científico publicado en 2017

Might dolutegravir be part of a functional cure for HIV?

artículo científico publicado en 2016

Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review

scientific article published on 31 May 2016

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection

artículo científico publicado en 2020

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity

artículo científico publicado en 2016

Positive and negative control of virus-induced interferon-A gene expression

artículo científico publicado en 2003

Proceedings of the Frontiers of Retrovirology Conference 2016.

artículo científico publicado en 2016

Productive entry of HIV-1 during cell-to-cell transmission via dynamin-dependent endocytosis

artículo científico publicado en 2013

Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir

artículo científico publicado en 2020

Reply to Achieng and Riedel

artículo científico publicado en 2019

Reply to Darcis and Berkhout

scientific article published on 01 November 2018

Repression by homeoprotein pitx1 of virus-induced interferon a promoters is mediated by physical interaction and trans repression of IRF3 and IRF7

artículo científico publicado en 2002

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

artículo científico publicado en 2015

Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors

artículo científico publicado en 2014

Resistance to HIV integrase inhibitors.

artículo científico

Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.

artículo científico publicado en 2015

Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor

artículo científico publicado en 2015

The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.

artículo científico publicado en 2015

The E3 ubiquitin ligase Triad3A negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation

artículo científico publicado en 2009

The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir

artículo científico publicado en 2016

The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness

artículo científico publicado en 2014

The POU transcription factor Oct-1 represses virus-induced interferon A gene expression

artículo científico publicado en 2005

The R262K substitution combined with H51Y in HIV-1 subtype B integrase confers low-level resistance against dolutegravir

artículo científico publicado en 2014

The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration

artículo científico publicado en 2017

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound

artículo científico publicado en 2014

The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B.

artículo científico publicado en 2015

The S230R Integrase Substitution Associated with Viral Rebound during DTG Monotherapy Confers Low Levels INSTI Drug Resistance.

artículo científico publicado en 2018

The antimalarial drug amodiaquine possesses anti-ZIKA virus activities.

artículo científico publicado en 2018

The development of novel HIV integrase inhibitors and the problem of drug resistance.

artículo científico

The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir

artículo científico publicado en 2015

The dual CCR5 and CCR2 inhibitor cenicriviroc does not redistribute HIV into extracellular space: implications for plasma viral load and intracellular DNA decline.

artículo científico publicado en 2014

The latest evidence for possible HIV-1 curative strategies

artículo científico publicado en 2018

Transcriptional re-programming of primary macrophages reveals distinct apoptotic and anti-tumoral functions of IRF-3 and IRF-7.

artículo científico publicado en 2009

Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation

artículo científico publicado en 2008

Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

artículo científico publicado en 2013

What if HIV were unable to develop resistance against a new therapeutic agent?

artículo científico publicado en 2013

Where are we with injectables against HIV infection and what are the remaining challenges?

artículo científico publicado en 2018

Will LEDGIN molecules be able to play a role in a cure for HIV infection?

artículo científico publicado en 2016

p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes

artículo científico publicado en 2011

Lista de obras de Thibault Mesplède

A high-throughput assay for HIV-1 integrase 3'-processing activity using time-resolved fluorescence

A resveratrol analog termed 3,3',4,4',5,5'-hexahydroxy-trans-stilbene is a potent HIV-1 inhibitor

Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.

Antimalarial drugs and their metabolites are potent Zika virus inhibitors

Antiviral Activity of Bictegravir and Cabotegravir Against Integrase Inhibitor Resistant SIVmac239 and HIV-1.

Automethylation of protein arginine methyltransferase 6 (PRMT6) regulates its stability and its anti-HIV-1 activity.

Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications

Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase.

Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase.

Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc

Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.

Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir

Combination of the R263K and M184I/V resistance substitutions against dolutegravir and lamivudine decreases HIV replicative capacity.

Combination therapies currently under investigation in phase I and phase II clinical trials for HIV-1

Correction for Anstett et al., "HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone Acetyltransferase Activity"

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors

Development of a fluorescence-based HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors.

Differences among HIV-1 subtypes in drug resistance against integrase inhibitors

Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase

Diverse Types of Diterpenoids with an Aromatized C Ring from the Twigs of Podocarpus imbricatus

Does antiretroviral treatment change HIV-1 codon usage patterns in its genes: a preliminary bioinformatics study

Dolutegravir inhibits HIV-1 Env evolution in primary human cells

Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout

Dolutegravir monotherapy of simian immunodeficiency virus-infected macaques selects for several patterns of resistance mutations with variable virological outcomes

Dolutegravir reshapes the genetic diversity of HIV-1 reservoirs.

Dolutegravir resistance mutation R263K cannot coexist in combination with many classical integrase inhibitor resistance substitutions

Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.

Durable suppression of HIV-1 with resistance mutations to integrase inhibitors by dolutegravir following drug washout

Effect of HIV-1 integrase resistance mutations when introduced into SIVmac239 on susceptibility to integrase strand transfer inhibitors

Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses

Erratum for Mesplède et al., "The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration"

Evolution of HIV integrase resistance mutations.

Exploring an alternative explanation for the second phase of viral decay: Infection of short-lived cells in a drug-limited compartment during HAART

Exposure to entry inhibitors alters HIV infectiousness and sensitivity to broadly neutralizing monoclonal antibodies.

Fitness impaired drug resistant HIV-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency

HIV Drug Resistance and the Advent of Integrase Inhibitors.

HIV drug resistance against strand transfer integrase inhibitors

HIV gp120 H375 is unique to HIV-1 subtype CRF01_AE and confers strong resistance to the entry inhibitor BMS-599793, a candidate microbicide drug.

HIV-1 Group O Resistance Against Integrase Inhibitors

HIV-1 group O integrase displays lower enzymatic efficiency and higher susceptibility to raltegravir than HIV-1 group M subtype B integrase

HIV-1 group O integrase displays lower susceptibility to raltegravir and has a different mutational pathway for resistance than HIV-1 group M.

HIV-1 resistance dynamics in patients failing dolutegravir maintenance monotherapy.

HIV-1 resistance to dolutegravir is affected by cellular histone acetyltransferase activity

Identification of a dibenzocyclooctadiene lignan as a HIV-1 non-nucleoside reverse transcriptase inhibitor

Identification of resveratrol analogs as potent anti-dengue agents using a cell-based assay

Implications for the future of the HIV epidemic if drug resistance against dolutegravir cannot occur in first-line therapy

Inhibition of NF-κB-dependent HIV-1 replication by the marine natural product bengamide A.

Insertion as a Resistance Mechanism Against Integrase Inhibitors in Several Retroviruses

Integrase Strand Transfer Inhibitors in HIV Therapy.

Integrase strand transfer inhibitors in the management of HIV-positive individuals

Investigational HIV integrase inhibitors in phase I and phase II clinical trials

Investigational drugs for the treatment of Zika virus infection: a preclinical and clinical update

Involvement of TBK1 and IKKepsilon in lipopolysaccharide-induced activation of the interferon response in primary human macrophages

Is resistance to dolutegravir possible when this drug is used in first-line therapy?

IκB kinase ε-dependent phosphorylation and degradation of X-linked inhibitor of apoptosis sensitizes cells to virus-induced apoptosis

JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1.

Lamivudine-resistant HIVM184V is durably suppressed with dolutegravir plus lamivudine dual therapy in humanised mice

M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.

Might dolutegravir be part of a functional cure for HIV?

Nonhuman Primates and Humanized Mice for Studies of HIV-1 Integrase Inhibitors: A Review

Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection

Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity

Positive and negative control of virus-induced interferon-A gene expression

Proceedings of the Frontiers of Retrovirology Conference 2016.

Productive entry of HIV-1 during cell-to-cell transmission via dynamin-dependent endocytosis

Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir

Reply to Achieng and Riedel

Reply to Darcis and Berkhout

Repression by homeoprotein pitx1 of virus-induced interferon a promoters is mediated by physical interaction and trans repression of IRF3 and IRF7

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence

Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors

Resistance to HIV integrase inhibitors.

Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.

Structural Studies of the HIV-1 Integrase Protein: Compound Screening and Characterization of a DNA-Binding Inhibitor

The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.

The E3 ubiquitin ligase Triad3A negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation

The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir

The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness